BREAST CANCER IN YOUNG PATIENTS. PECULIARITIES OF PROGNOSIS AND ADIUVANT HORMONE THERAPY (A LITERATURE REVIEW)


Cite item

Full Text

Abstract

Breast cancer (BC) keeps being the most predominant malignant disease in women. In recent years, a trend towards “rejuvenescence” of the disease has been observed that affects its features. Despite modern methods of diagnosis and complex treatment used in young patients, survival in this age group are inferior that's associated with biological and morphological peculiarities of BC in young age. Gradually collected data demonstrates that age might be an independent factor exacerbating prognosis. For BC patients younger 40 years, various aspects of hormone therapy remain ambiguous: prolonged tamoxifen use, aromatase inhibitors prescription, ovarian function suppression, a role of chemotherapy-induced amenorrhea on prognosis of young BC patients. The issue of appropriate, personalized adjuvant hormone therapy of BC is complex and heterogenous that requires a necessity to further international randomized trials.

About the authors

D N Kravchenko

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

Email: juramento@yandex.ru
аспирант

A A Parokonnaya

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

Email: ANAPAR1@yandex.ru
д.м.н

M I Nechushkin

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

д.м.н., профессор

E A Nikitina

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

Email: katuwa689@yandex.ru
аспирант

N D Hakurinova

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

Email: nafset2701@mail.ru
аспирант

References

  1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, et al. Int J Cancer 2010;127:2893-917.
  2. Статистика злокачественных новообразований женских половых органов Е.М. Аксель ОЖРС 2009 (1-2):76-80.
  3. Адъювантная гормонотерапия рака молочной железы длительностью 10 лет: за и против. С.М. Портной, Т.А. Шендрикова, Опухоли женской репродуктивной системы, №3-4, 50-53, 2013.
  4. Состояние онкологической помощи населению России в 2015 году под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой, ISBN 978-5-85502-226-1, 18 (2016) http://oncology-association.ru/docs/medstat/ sostoyznie/2015.pdf
  5. Злокачественные новообразования в России в 2010г. Под ред.В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012, 260с.
  6. Статистика злокачественных новообразований в России и странах СНГ в 2011г. Давыдов М.И., Аксель E.М. Вестн РОНЦ 2011; 22 (3 прил 1):57.
  7. Онкоэндокринология. Традиции, современность и перспективы. Берштейн Л.М. СПб.Наука. 2004.
  8. Катехолэстрогены: образование, свойства и роль в канцерогенезе. Вопр онкол 1997;43(3):257-62.
  9. Клинико-морфологические характеристики и прогноз BRCA-ассоциированного рака молочной железы у женщин репродуктивного возраста Д.Е. Автомонов, А.А. Пароконная, Л.Н. Любченко, М.И. Нечушкин, Н.И. Поспехова. ОЖРС 2012; (1): 20-23.
  10. Breast cancer statistics, 2011. DeSantis C, Siegel R, Bandi P, et al. CA Cancer J Clin 2011;61:409-18.
  11. Breast cancer before age 40 years. Anders CK, Johnson R, Litton J, et al. Semin Oncol 2009;36:237-49.
  12. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer F.Torino, A.Barnabei, L.de Vecchis, V.Sini, F.Schittulli Oncology Hematology 89, 27-42, 2014.
  13. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. Samphao S, Wheeler AJ, Rafferty E, et al. Am J Surg 2009;198:538-43.
  14. Hai-long Chen, Mei-qi Zhou, Wei Tian, Ke-xin Meng, and Hai-fei He2PLoS One. 2016; 11(10): e0165409. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database.
  15. Optimal adjuvant therapy for very young breast cancer patients Prudence A. Francis The Breast 20, 297-302, 2011.
  16. Breast. 2013 Aug;22 Suppl 2:S176-9. doi: 10.1016/j. breast.2013.07.034.Management of breast cancer in very young women. Freedman RA1, Partridge AH.
  17. Статистика злокачественных новообразований в России и странах СНГ в 2004г. Давыдов М.И., Аксель Е.М. Вестн РОНЦ 2006; 17 (3):132.
  18. Breast cancer in young women Courtney A Gabriel, Susan M Domchek Breast Cancer Research, 2010, 12:2012.
  19. Настоящее и будущее антиHer-2-терапии рака молочной железы Летягин В.П. ОЖРС 2011; 2:41-4
  20. Практическое руководство по клинической маммологии Давыдов М.И., Летягин В.П. М., 2004. С.5-7.
  21. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Anders CK, Hsu DS, Broadwater G, et al. J Clin Oncol 2008;26:3324-30.
  22. de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.
  23. Effects of young age at presentation on survival in breast cancer. El Saghir NS, Seoud M, Khalil MK, et al. BMC Cancer 2006;6:194.
  24. Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. Bharat A, Aft RL, Gao F, et al. J Surg Oncol 2009;100:248-51.
  25. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. Han W, Kim SW, Park IA, et al. BMC Cancer 2004;4:82.
  26. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. Gnerlich JL, Deshpande AD, Jeffe DB, et al. J Am Coll Surg 2009;208:341-7.
  27. Carey K. Anders, David S. Hsu, Gloria Broadwater, et al. Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression. J Clin Oncol 26:3324-3330.
  28. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Azim HA Jr, Michiels S, Bedard PL, et al. Clin Cancer Res 2012;18:1341-51.
  29. Aleyamma Mathew, Balakrishnan Rajan and Manoj Pandey. Do younger women with non-metastatic and noninflammatory breast carcinoma have poor prognosis? World Journal of Surgical Oncology 2004, 2:2
  30. Nagi S El Saghir, Muhieddine Seoud, Mazen K Khalil. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006, 6:194.
  31. Chen H., Zhou M., Tian W. Effects of age on breast cancer patient prognoses: a population-based study using the SeEr 18 database. PloS One. 2016 Oct 31; 11 (10).
  32. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials Sibylle Loibl, Christian Jackisch, Bianca Lederer. Breast Cancer Res Treat (2015) 152:377-387.
  33. Adjuvant endocrine therapy for premenopausal women with early breast cancer Ting Bao, Nancy Davidson, Breast Cancer Research 9:115, 256-259, 2007.
  34. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer R.Torrisi, V.Bagnardi, N.Rotmensz, E.Scorano, M.Iorfida, P.Veronesi Breast Cancer res treat doi: 10.1007/s10549-010-1340-y 2011
  35. Ohtani H, Mori-Shiraishi K, Nakajima M. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int. 2015 Dec;65(12):644-51. doi: 10.1111/pin.12355.
  36. Hatem A. Azim Jr., MD, PhD, Nancy E. Davidson, MD, and Kathryn J. Ruddy. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. 2016 ASCO EDUCATIONAL BOOK, 23-32.
  37. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer Rachel C. Jankowitz*, Kandace P. McGuire 1 , Nancy E. Davidson The Breast 22 (2013) S165-S170.
  38. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Gray RG, Rea D, Handley D, Bowden SJ, Perry P (2013) J Clin Oncol 31, 2013.
  39. Extended Adjuvant Tamoxifen for early breast cancer: a meta-analysis. Mustafa Al-Mubarak, Ariadna Tibau, Arnoud J.Templeton. PLoS One 2014 9(2):1-9
  40. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Davies C., Pan H., Godwin J., Gray R. Lancet 2012 (4):61963-61961.
  41. Breast cancer in young women. Brennan M, French J, Houssami N, et al. Aust Fam Physician 2005;34:851-5.
  42. Role of Goserelin in Combination with Endocrine Therapy for the Treatment of Advanced Breast Cancer in Premenopausal Women Positive for Hormone Receptor: A Retrospective Matched Case-Control Study, Sangang Wu, Qun Li, Yuliang Zhu, Cancer biotherapy and pharmaceuticals 0, 1-7, 2013.
  43. Strategies for subtypesdealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer Goldhirsch A, Wood W C, Coates AS, et al. Annals of Oncology 2011;22:1736-47.
  44. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Smith IE, Dowsett M, Yap Y S, et al. Journal of Clinical Oncology 2006;24:2444-7
  45. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care Shannon Puhalla, Saveri Bhattacharaya, Nancy E.Davidson, Molecular Oncology 6, 222-236, 2012.
  46. Возможности адъювантной эндокринной терапии рака молочной железы (часть 1) Н.Ю. Добровольская, Э.К. Ввозный, Ю.М. Бычков ОжРС 2008 (3):54-57.
  47. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive breast cancer: an intergroup study Taylor C.W., Green S., Dalton W.S., Journal of Clinical Oncology 16, 994-999, 1998.
  48. Лапароскопические операции на матке и ее придатках у больных раком молочной железы С.Ю. Слетина, И.Г. Комаров, Д.В. Комов, Т.М. Кочоян, А.В. Волобуев ОЖРС 2008 (2):23-26.
  49. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care Shannon Puhalla, Saveri Bhattacharaya, Nancy E.Davidson, Molecular Oncology 6, 222-236, 2012.
  50. Осложнения в лапароскопической хирургии и их профилактика Седов В.М., Стрижелецкий В.В. СПб., Санкт-Петербургское медицинское издательство; 2002.
  51. A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberth M, et al. Eur J Cancer. 2007;43:2351-8.
  52. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, et al. Breast Cancer Res Treat. 2011;128:755-63.
  53. Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea. Juan Zhou, San-Gang Wu, Jun-Jie Wang. Cancer Res Treat 2014:1-9
  54. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. LHRH-agonists in Early Breast Cancer Overview Group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, et al. Lancet. 2007;369:1711-23.
  55. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, et al. Eur J Cancer. 2006;42:895-904.
  56. StGallen International Expert Consensus on the primary therapy of early breast cancer, Annals of Oncology, 2015.
  57. Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy Halle C.F. Moore, M.D., Joseph M. Unger, Ph.D., Kelly Anne, Phillips, M.D., NEJM 372;10, 923-932, 2015.
  58. Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline F.Y.F.L. de Vos, H.W.M. van Laarhoven, Critical Reviews in Oncology/Hematology 84, 252-260, 2012.
  59. Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels K.Meng, W.Tian, M.Zhou World Journal of Surgical Oncology 11:101, 325-332, 2013.
  60. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. Walshe JM, Denduluri N, Swain SM. J Clin Oncol. 2006;24:5769-79.
  61. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Arriagada R, Le MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, et al. Ann Oncol. 2005;16:389-96.
  62. Вспомогательные репродуктивные технологии в сохранении репродуктивной функции онкологических больных М.В. Киселева, Е.В. Абакушина, А.Ф. Цыб ОЖРС 2009 (1-2):108-111.
  63. Беременность у женщин, перенесших рак молочной железы А.А. Пароконная, М.И. Нечушкин, Л.Н. Любченко, Е.Б. Кампова-Полевая ОЖРС 2009 (1-2):67-71.
  64. N. Biglia, F. A. Peccatori. Breast cancer, fertility preservation and reproduction. 2015. P. 17.
  65. Longer therapy, iatrogenic menorrhea, and survival in early breast cancer. Swain SM, Jeong JH, Geyer Jr CE, et al. New England Journal of Medicine;362:2053-65, 2010.
  66. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Pagani O, O’Neill A, Castiglione M, Gelber Rd, Goldhirsch A, Rudenstam CM, et al. Eur J Cancer. 1998;34:632-40.

Copyright (c) 2017 Kravchenko D.N., Parokonnaya A.A., Nechushkin M.I., Nikitina E.A., Hakurinova N.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies